Related references
Note: Only part of the references are listed.Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management
Ayalew Tefferi
AMERICAN JOURNAL OF HEMATOLOGY (2012)
Circulating microparticles in carriers of factor V Leiden with and without a history of venous thrombosis
Elena Campello et al.
THROMBOSIS AND HAEMOSTASIS (2012)
Microparticles in tumor progression
Anna Falanga et al.
THROMBOSIS RESEARCH (2012)
Platelet-induced thrombin generation by the calibrated automated thrombogram assay is increased in patients with essential thrombocythemia and polycythemia vera
Marina Panova-Noeva et al.
AMERICAN JOURNAL OF HEMATOLOGY (2011)
Cellular Mechanisms Underlying the Formation of Circulating Microparticles
Olivier Morel et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2011)
Microparticles in Hemostasis and Thrombosis
A. Phillip Owens et al.
CIRCULATION RESEARCH (2011)
Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
Tiziano Barbui et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical relevance of microparticles from platelets and megakaryocytes
Joseph E. Italiano et al.
CURRENT OPINION IN HEMATOLOGY (2010)
Increased circulating procoagulant activity and thrombin generation in patients with myeloproliferative neoplasms
Jerome Duchemin et al.
THROMBOSIS RESEARCH (2010)
Platelet turnover, coagulation factors, and soluble markers of platelet and endothelial activation in essential thrombocythemia: Relationship with thrombosis occurrence and JAK2 V617F allele burden
Eduardo Arellano-Rodrigo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2009)
Microparticles and thrombotic disease
Pavel Davizon et al.
CURRENT OPINION IN HEMATOLOGY (2009)
Elevated procoagulant microparticles expressing endothelial and platelet markers in essential thrombocythemia
Marijke C. Trappenburg et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: A systematic review
Federico Lussana et al.
THROMBOSIS RESEARCH (2009)
Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera
Marina Marchetti et al.
BLOOD (2008)
Microparticles in Health and Disease
Anoop K. Enjeti et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2008)
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules
Anna Falanga et al.
EXPERIMENTAL HEMATOLOGY (2007)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Alessandra Carobbio et al.
BLOOD (2007)
V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules (vol 35, jpg 702, 2007)
A. Falanga et al.
EXPERIMENTAL HEMATOLOGY (2007)
Leukocytosis, JAK2(V617F) Mutation, and Hemostasis in Myeloproliferative Disorders
Marina Marchetti et al.
PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS (2007)
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia
B Cheung et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: The role of neutrophils
A Falanga et al.
SEMINARS IN HEMATOLOGY (2005)
Chronic myeloproliferative disorders. The new WHO classification
J Thiele et al.
PATHOLOGE (2001)
Share Paper
